Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2007 1
2008 2
2009 5
2010 6
2011 8
2012 11
2013 12
2014 16
2015 9
2016 9
2017 14
2018 18
2019 20
2020 17
2021 19
2022 23
2023 27
2024 21
2025 25
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Karimzadeh A, Lehnert W, Koehler D, Shenas F, Kisters A, Apostolova I, Klutmann S, Adam G, Sauer M. Karimzadeh A, et al. Nuklearmedizin. 2025 Aug;64(4):262-271. doi: 10.1055/a-2654-4048. Epub 2025 Aug 6. Nuklearmedizin. 2025. PMID: 40769164 Review. English.
Response evaluation is based on imaging, PSA levels, and the patient's clinical condition.. . Karimzadeh A, Lehnert W, Koehler D et al. Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic cast …
Response evaluation is based on imaging, PSA levels, and the patient's clinical condition.. . Karimzadeh A, Lehnert W, Koehler …
Moving toward a contemporary classification of drug-induced kidney disease.
Karimzadeh I, Barreto EF, Kellum JA, Awdishu L, Murray PT, Ostermann M, Bihorac A, Mehta RL, Goldstein SL, Kashani KB, Kane-Gill SL. Karimzadeh I, et al. Crit Care. 2023 Nov 9;27(1):435. doi: 10.1186/s13054-023-04720-2. Crit Care. 2023. PMID: 37946280 Free PMC article. Review.
Medications were stratified into four categories, including "dysfunction without damage," "damage without dysfunction," "both dysfunction and damage," and "neither dysfunction nor damage" using this novel framework along with predominant mechanism(s) of nephrotoxicity for …
Medications were stratified into four categories, including "dysfunction without damage," "damage without dysfunction," "both dysfunction an …
Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Karimzadeh A, Lehnert W, Koehler D, Shenas F, Kisters A, Apostolova I, Klutmann S, Adam G, Sauer M. Karimzadeh A, et al. Rofo. 2025 Sep;197(9):1033-1042. doi: 10.1055/a-2514-4523. Epub 2025 Jan 22. Rofo. 2025. PMID: 39842443 Free article. Review. English.
Response evaluation is based on imaging, PSA levels, and the patient's clinical condition.. . Karimzadeh A, Lehnert W, Koehler D et al. Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic cast …
Response evaluation is based on imaging, PSA levels, and the patient's clinical condition.. . Karimzadeh A, Lehnert W, Koehler …
Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer.
Karimzadeh M, Momen-Roknabadi A, Cavazos TB, Fang Y, Chen NC, Multhaup M, Yen J, Ku J, Wang J, Zhao X, Murzynowski P, Wang K, Hanna R, Huang A, Corti D, Nguyen D, Lam T, Kilinc S, Arensdorf P, Chau KH, Hartwig A, Fish L, Li H, Behsaz B, Elemento O, Zou J, Hormozdiari F, Alipanahi B, Goodarzi H. Karimzadeh M, et al. Nat Commun. 2024 Nov 21;15(1):10090. doi: 10.1038/s41467-024-53851-9. Nat Commun. 2024. PMID: 39572521 Free PMC article.
microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer.
Nahand JS, Taghizadeh-Boroujeni S, Karimzadeh M, Borran S, Pourhanifeh MH, Moghoofei M, Bokharaei-Salim F, Karampoor S, Jafari A, Asemi Z, Tbibzadeh A, Namdar A, Mirzaei H. Nahand JS, et al. J Cell Physiol. 2019 Aug;234(10):17064-17099. doi: 10.1002/jcp.28457. Epub 2019 Mar 19. J Cell Physiol. 2019. PMID: 30891784 Review.
A High-Throughput Yellow Fever Neutralization Assay.
Rasulova M, Vercruysse T, Paulissen J, Coun C, Suin V, Heyndrickx L, Ma J, Geerts K, Timmermans J, Mishra N, Li LH, Kum DB, Coelmont L, Van Gucht S, Karimzadeh H, Thorn-Seshold J, Rothenfußer S, Ariën KK, Neyts J, Dallmeier K, Thibaut HJ. Rasulova M, et al. Microbiol Spectr. 2022 Jun 29;10(3):e0254821. doi: 10.1128/spectrum.02548-21. Epub 2022 Jun 7. Microbiol Spectr. 2022. PMID: 35670599 Free PMC article.
Massively multiplex single-molecule oligonucleosome footprinting.
Abdulhay NJ, McNally CP, Hsieh LJ, Kasinathan S, Keith A, Estes LS, Karimzadeh M, Underwood JG, Goodarzi H, Narlikar GJ, Ramani V. Abdulhay NJ, et al. Elife. 2020 Dec 2;9:e59404. doi: 10.7554/eLife.59404. Elife. 2020. PMID: 33263279 Free PMC article.
Broadening the phenotype and genotype spectrum of novel mutations in pontocerebellar hypoplasia with a comprehensive molecular literature review.
Ghasemi MR, Tehrani Fateh S, Moeinafshar A, Sadeghi H, Karimzadeh P, Mirfakhraie R, Rezaei M, Hashemi-Gorji F, Rezvani Kashani M, Fazeli Bavandpour F, Bagheri S, Moghimi P, Rostami M, Madannejad R, Roudgari H, Miryounesi M. Ghasemi MR, et al. BMC Med Genomics. 2024 Feb 13;17(1):51. doi: 10.1186/s12920-024-01810-0. BMC Med Genomics. 2024. PMID: 38347586 Free PMC article.
Treatment for vestibular schwannoma: Systematic review and single arm meta-analysis.
Thai NLB, Mai NY, Vuong NL, Tin NM, Karam D, Refaey MA, Shahin KM, Soliman AL, Al Khudari R, Thuan TM, Sabbah GM, El-Qushayri AE, Karimzadeh S, Hirayama K, Huy NT. Thai NLB, et al. Am J Otolaryngol. 2022 Mar-Apr;43(2):103337. doi: 10.1016/j.amjoto.2021.103337. Epub 2021 Dec 20. Am J Otolaryngol. 2022. PMID: 34973662
We assessed the risk of bias using ROBIN-I's tool and scale of Council Australia's Cancer Guidelines Wiki. The protocol was registered in PROSPERO (CRD42018089784) and has been updated on 17 April 2019. ...
We assessed the risk of bias using ROBIN-I's tool and scale of Council Australia's Cancer Guidelines Wiki. The protocol was re …
240 results